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Background: Studies have reported on the incidence of sedation-related adverse events (AEs), 
but little is known about their impact on health care costs and resource use.
Methods: Health care providers and payers in five countries were recruited for an online survey 
by independent administrators to ensure that investigators and respondents were blinded to each 
other. Surveys were conducted in the local language and began with a “screener” to ensure that 
respondents had relevant expertise and experience. Responses were analyzed using Excel and 
R, with the Dixon’s Q statistic used to identify and remove outliers. Global and country-specific 
average treatment patterns were calculated via bootstrapping; costs were mean values. The sum 
product of costs and intervention probability gave a cost per AE.
Results: Responses were received from 101 providers and 26 payers, the majority having 5 years 
of experience. At a minimum, the respondents performed a total of 3,430 procedural sedations 
per month. All AEs detailed occurred in clinical practice in the last year and were reported to 
cause procedural delays and cancellations in some patients. Standard procedural sedation costs 
ranged from €74 (Germany) to $2,300 (US). Respondents estimated that AEs would increase 
costs by between 16% (Italy) and 179% (US). Hypotension was reported as the most commonly 
observed AE with an associated global mean cost (interquartile range) of $43 ($27–$68). Other 
frequent AEs, including mild hypotension, bradycardia, tachycardia, mild oxygen desaturation, 
hypertension, and brief apnea, were estimated to increase health care spending on procedural 
sedation by $2.2 billion annually in the US.
Conclusion: All sedation-related AEs can increase health care costs and result in substantial 
delays or cancellations of subsequent procedures. The prevention of even minor AEs during 
procedural sedation may be crucial to ensuring its value as a health care service.
Keywords: costs, complications, moderate sedation, questionnaire, survey, health care payers
Introduction
Sedation and anesthesia are an important means of providing patient comfort, safety, 
and clinical stability during invasive and/or uncomfortable medical procedures. Use of 
procedural sedation is considered to be on the rise. For example, a recent meta-analysis 
reported a steady increase in rates of procedural sedation for gastrointestinal procedures 
from around 10% in 2000 to 30% in 2010 in the US.1 A separate trend analysis indicated 
that of nonoperating room procedures, 69.7% in 2010 and 73.3% in 2014 used sedation.2 
The use of procedural sedation is expected to continue to grow, in part due to advances 
in minimally invasive operative techniques and evidence that its use improves patient 
outcomes.3 Concomitantly, patients’ expectations regarding comfort, safety and clinical 
outcomes have increased, making sedation quality an important area of investigation.4
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Procedural sedation carries inherent patient risks and 
requires careful monitoring of patients’ vital signs. Both 
US (American Society of Anesthesiologists) and European 
(European Board of Anaesthesiology and European Society of 
Anaesthesiology) recommendations in this regard are broadly 
in agreement, requiring minimum measures of oxygenation 
(pulse oximetry), circulation (non-invasive blood pressure), 
and ventilation (capnography).5,6 Despite best monitoring 
practices, however, adverse events (AEs) related to sedation 
still occur, with hypotension and hypoxemia among the most 
commonly reported.7 These AEs have been documented 
across all studies of sedation, although the definitions used 
for each have been heterogeneous and rates have varied by 
study type. For example, prospective randomized controlled 
trials8–11 have generally reported higher rates of sedation-
related AEs compared with retrospective studies.12–14
Given the potential for sedation-related AEs, providers 
around the world have learned to choose sedation plans that 
consider both safety and costs. Optimization of sedation 
planning requires knowledge of current clinical practice 
in sedation and monitoring, how AEs are perceived and 
treated and potential costs should an AE occur. Many clinical 
practice reviews focus on discussions of ideal agents,15 risk 
stratification of subpopulations,16,17 and/or settings.12,16 
Although informative, these focused studies have provided 
neither a generalized overview of sedation practice in a global 
context nor an informed perspective on AE management or 
costs. As such, the precise data required to inform value-based 
decisions around sedation practices have not been available.
Our study was designed to address this data gap and 
provide a global context that could be useful to providers 
and payers involved in the administration of procedural 
sedation. We sought to estimate the economic burden of 
sedation-related AEs across multiple countries and medical 
practices. Our aim was to understand current clinical sedation 
practice used by different providers and interventions used to 
treat AEs, as defined by the World Society for Intravenous 
Anesthesia (SIVA) task force on procedural sedation.18 
We also obtained survey data from local payers on the cost 
of interventions and resource use, and our analyses provide 
a first look at global practice in management of AEs, finding 
both consistencies in practice and variations in costs associ-
ated with sedation-related AEs.
Materials and methods
The aim of our study was to provide an estimate of the 
cost of AEs associated with sedation from the perspective 
of the hospital payer. Two surveys were prepared: one for 
providers qualified to oversee procedural sedation and one 
for payers (allowing those in clinics, hospitals, or medical 
offices or state health insurers to participate). Both surveys 
were designed and reviewed by the study authors and admin-
istered by a third party (GfK Switzerland), thereby blinding 
the authors to participants and vice versa. As this was a pilot 
study, no power calculations were performed to determine a 
sample size for number of respondents required per country; 
20 providers and five payers were deemed feasible quotas 
for each target country. Surveys were designed in English 
(administered in the UK and US) and performed in local 
language in France, Germany and Italy.
Our study was designed as a general survey of practice 
patterns and costing data and involved surveying an array 
of individuals in different roles across different institutions 
worldwide about their knowledge, attitudes and beliefs. No 
patient-level data were included, and the survey was not 
subject to an institutional review process. Survey respondents 
provided informed consent for participation in the research 
and its publication through direct enquiry by reading and 
agreeing to an introductory statement explaining the purpose 
and use of the data prior to completing the survey items.
Each survey consisted of two sections: a screener and 
a questionnaire. The screener questions ensured that only 
respondents with relevant expertise and experience com-
pleted the questionnaire. Screener questions included items 
such as time employed in health care and number of proce-
dural sedations administered per month.
The provider questionnaire collected data on sedation 
agents, patient monitoring practices, relative incidence of 
AEs encountered, common management strategies for AEs, 
and outcomes following AEs (Supplementary materials). 
For treatment and outcomes of AEs, respondents were 
provided an AE and its SIVA definition and were asked 
to provide whole numbers of patients who would receive 
a corresponding treatment (including no treatment) from a 
list of SIVA-defined interventions. In the interest of reduc-
ing the time burden to complete the survey, only a subset of 
AEs was presented to each respondent. These AEs queried 
were random unless a respondent indicated that they had 
experience with a rare AE, in which case the rare event was 
preferentially queried.
The payer questionnaire collected data on the direct 
and comprehensive (or “fully loaded” costs, inclusive of 
administration, management, quality, legal and transport 
services) costs of procedural sedation (including all SIVA-
defined interventions) and health care resources (including 
provider time). Respondents were also asked to provide the 
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overall cost of an uncomplicated procedural sedation and then 
to estimate the percentage increase in costs resulting from 
procedural sedation-related complications. Costs provided 
were those determined by the individual payer respondent; 
no specific costing methodology was enforced on the payer 
by the survey. Owing to high degrees of variability and sub-
jectivity, particularly regarding potential legal obligations, 
only the direct costs of interventions were used to calculate 
costs of AEs in this study. These results were compared 
to the overall (“fully loaded”) costs reported by payers for 
procedures with sedation-related complications. Values were 
entered in the local currencies, where “0” indicated no direct 
costs to the institution.
Data were first assessed in Microsoft Excel, with subse-
quent cleaning and analysis performed using Microsoft Excel 
and R. Analysis of AEs and treatment patterns adopted an 
“identify and replace” strategy for response outliers. Outliers 
(at the 95% confidence level or p-value 0.05, Dixon’s Q test) 
were replaced with the global mean for that combination of 
AE and treatment response. Average treatment patterns 
were calculated via the weighted mean treatment pattern 
per AE per country. Higher weight was given to respondents 
who reported more experience of the AE, and lower weight 
was given to respondents with more outlier responses. Global 
median patterns and interquartile ranges (IQRs) were derived 
from 10,000 bootstrap replicates. Statistical inference testing 
was performed using nonparametric methods. To assess 
differences among multiple groups, the Kruskal–Wallis 
test was applied at p-value 0.05 for significance of results.
Payer respondents had the option to report no cost or cost 
unknown, resulting in anywhere from two to five responses 
for cost items in each country. Since these counts were low, 
bootstrapping was not performed to estimate uncertainties. 
Instead, a simple mean of the provided values was calculated 
in the local currency.
Analysis of costs was performed with the same outlier 
identification strategy. Costs were obtained in February 2017 
and March 2017 and were assumed to represent costs for the 
2016–2017 period. The overall direct cost of each AE was 
calculated in two parts, the intervention cost and the personnel 
cost. As the first step in calculating costs of sedation-related 
AEs, provider data were analyzed to determine the frequen-
cies at which various interventions were used to address the 
presented AEs. The intervention frequencies were multiplied 
by the payer-reported costs of individual interventions to 
estimate the intervention cost of each AE. Time to treat the 
AE was multiplied by the number of providers present and 
the mean reported wage to determine the personnel burden. 
Combining costs and treatment patterns, the mean cost per 
AE per country was calculated, and a “global mean cost” was 
determined by first converting each country’s mean cost to 
2016 USD using the average annual exchange rate from the 
Internal Revenue Service of the US. The average of the five 
countries was taken as the global mean cost.
Results
Demographics
Respondents to the provider survey comprised multiple 
medical practices and settings, with most having 5 years 
of experience (Table 1). At a minimum, the 101 providers 
sampled represent 3,430 procedural sedations per month: 
France (700), Germany (730), Italy (700), UK (550) and 
US (750).
There were 26 respondents to the payer survey, with six 
respondents in France and five each in the other countries. 
The majority (23) were hospital-employed payers, with two 
employed by a clinic and one in a national health service. 
Most common job titles were department head (six), procure-
ment (five), and manager (five). All included responsibility 
for purchasing, pricing, and/or resources.
expected costs of procedural sedation
Prior to calculation of costs of complications in procedural 
sedation, the payer data were used to provide an overview 
of current estimates of overall sedation costs. The payer 
responses revealed wide differences in the costs of procedural 
sedation and the impact of complications (Table 2) with mean 
costs ranging from EUR 74 in Germany to USD 2,300 in the 
US. Complications resulted in cost increases of 12% (Italy) 
to 78% (Germany) with a global mean of 47%.
Current clinical practice
A snapshot of provider responses for current clinical practices 
found most were more likely to follow local hospital guidelines 
than national and society guidelines (Table 1). The use of 
sedation agents was broadly similar across settings, although 
use of fentanyl and ketamine showed differences by geogra-
phy (p0.01). Among respondents, the most common patient 
monitoring modality used was pulse oximetry, which was also 
most likely to be considered standard of care and to be used to 
guide clinical management (p0.05). The least used monitor-
ing modality among those analyzed was capnography.
aes and their treatment
All AEs surveyed were reported to have occurred in clinical 
practice in the last year by at least one respondent per country. 
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Global median treatment patterns for AEs are presented in 
Table 3, ordered by relative global incidence as reported 
by respondents from most frequent (hypotension) to least 
(seizure). Data were relatively consistent across countries; 
a test of AE/treatment pattern combinations across countries 
found that 89.4% of these were not significantly different at 
the 95% confidence level (p-value 0.05). Of the remaining 
10.6% with significant differences, the most inter-country 
Table 1 Demographics and select procedural sedation parameters of survey respondents
Item Global France Germany Italy UK US
n 101 (100.0%) 20 (100.0%) 20 (100.0%) 20 (100.0%) 20 (100.0%) 21 (100.0%)
Medical practice
sedation nurse 47 (46.5%) 9 (45.0%) 11 (55.0%) 7 (35.0%) 10 (50.0%) 10 (47.6%)
anesthesiologist 31 (30.7%) 10 (50.0%) 5 (25.0%) 5 (25.0%) 5 (25.0%) 6 (28.6%)
gastroenterologist 16 (15.8%) 0 (0.0%) 3 (15.0%) 8 (40.0%) 3 (15.0%) 2 (9.5%)
Cardiologist 3 (3.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.0%) 2 (9.5%)
Critical care specialist 3 (3.0%) 1 (5.0%) 1 (5.0%) 0 (0.0%) 1 (5.0%) 0 (0.0%)
Plastic surgeon 1 (1.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (4.8%)
associated setting
general hospital 52 (51.5%) 9 (45.0%) 14 (70.0%) 7 (35.0%) 12 (60.0%) 10 (47.6%)
University hospital 36 (35.6%) 9 (45.0%) 5 (25.0%) 8 (40.0%) 9 (45.0%) 5 (23.8%)
Private hospital 16 (15.8%) 0 (0.0%) 1 (5.0%) 6 (30.0%) 3 (15.0%) 6 (28.6%)
Private clinic 11 (10.9%) 3 (15.0%) 0 (0.0%) 3 (15.0%) 0 (0.0%) 5 (23.8%)
Physician’s office 5 (5.0%) 1 (5.0%) 0 (0.0%) 1 (5.0%) 0 (0.0%) 3 (14.3%)
hospital outpatient clinic 4 (4.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (19.0%)
ambulatory surgical center 2 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (9.5%)
Years of experience
5+ 8 (7.9%) 3 (15.0%) 0 (0.0%) 1 (5.0%) 3 (15.0%) 1 (4.8%)
2–5 93 (92.1%) 17 (85.0%) 20 (100.0%) 19 (95.0%) 17 (85.0%) 20 (95.2%)
Procedures per month
20–50 54 (53.5%) 10 (50.0%) 9 (45.0%) 10 (50.0%) 15 (75.0%) 10 (47.6%)
50+ 47 (46.5%) 10 (50.0%) 11 (55.0%) 10 (50.0%) 5 (25.0%) 11 (52.4%)
sedation agents used
Midazolam 93 (92.1%) 16 (80.0%) 17 (85.0%) 20 (100.0%) 20 (100.0%) 20 (95.2%)
Propofol 90 (89.1%) 19 (95.0%) 20 (100.0%) 18 (90.0%) 15 (75.0%) 18 (85.7%)
Fentanyl 75 (74.3%) 9 (45.0%) 16 (80.0%) 18 (90.0%) 18 (90.0%) 14 (66.7%)
Ketamine 56 (55.4%) 18 (90.0%) 10 (50.0%) 7 (35.0%) 9 (45.0%) 12 (57.1%)
Meperidine 15 (14.9%) 1 (5.0%) 2 (10.0%) 6 (30.0%) 4 (20.0%) 2 (9.5%)
Monitoring methods used
Pulse oximetry 99 (98.0%) 19 (95.0%) 20 (100.0%) 20 (100.0%) 19 (95.0%) 21 (100.0%)
heart rate 97 (96.0%) 18 (90.0%) 20 (100.0%) 19 (95.0%) 19 (95.0%) 21 (100.0%)
Blood pressure 95 (94.1%) 18 (90.0%) 20 (100.0%) 16 (80.0%) 20 (100.0%) 21 (100.0%)
eCg 91 (90.1%) 15 (75.0%) 20 (100.0%) 18 (90.0%) 17 (85.0%) 21 (100.0%)
Respiratory rate 82 (81.2%) 16 (80.0%) 15 (75.0%) 12 (60.0%) 18 (90.0%) 21 (100.0%)
Capnography 62 (61.4%) 11 (55.0%) 14 (70.0%) 8 (40.0%) 13 (65.0%) 16 (76.2%)
source of guidelines used
local 70 (69.3%) 12 (60.0%) 17 (85.0%) 10 (50.0%) 14 (70.0%) 17 (81.0%)
national 57 (56.4%) 12 (60.0%) 11 (55.0%) 10 (50.0%) 11 (55.0%) 13 (61.9%)
Professional society 43 (42.6%) 10 (50.0%) 13 (65.0%) 4 (20.0%) 4 (20.0%) 12 (57.1%)
international 17 (16.8%) 5 (25.0%) 3 (15.0%) 6 (30.0%) 2 (10.0%) 1 (4.8%)
Note: numbers in parentheses indicate percentages globally or by country.
Abbreviation: eCg, electrocardiography.
Table 2 Reported procedural sedation costs
Type of procedural sedation France (EUR) Germany (EUR) Italy (EUR) UK (GBP) US (USD)
Cost of uncomplicated procedure 550 (300–1,000) 74 (0–150) 263 (0–800) 570 (0–1,500) 2,030 (150–5,000)
Cost with sedation-related complication 857 (390–1,500) 132 (0–300) 294 (0–880) 758 (0–2,250) 3,200 (600–6,250)
estimated costs of complications 258 (90–500) 57 (0–150) 31 (0–80) 188 (0–750) 1,170 (400–2,500)
Notes: Payers were asked to provide costs for uncomplicated sedation procedures (“fully loaded” costs, inclusive of administration, management, quality, and legal and 
transport services) and individual costs of procedures with complications. The cost differences due to complications were calculated, and mean values and ranges were 
determined. all values are mean values with range in parentheses.
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variability occurred in reports of rates of nonintervention in 
Italy for prolonged apnea and varied greatly from responses 
by providers in Germany, the UK, and the US.
Time required to treat AEs was consistently found to 
be 1 minute, even for mild events. Variations occurred 
across countries, however, with US-based providers more 
likely to intervene for mild AEs compared to their European 
counterparts. Invasive interventions (eg, endotracheal intuba-
tion for airway [AW] support) were reported more likely to 
occur with serious AEs, such as cardiovascular collapse.
Costs of aes
Payers reported all treatment responses (except “none”) had 
an associated cost. In contrast to the range of procedural 
sedation costs and variation in the impact of AEs on these 
costs as provided by payers (Table 2), the costs of AEs per 
procedure were found to be relatively consistent among 
countries (Table 4). The global median costs for cardiac 
arrest ($575) and cardiovascular collapse ($217) were the 
most expensive, while hypotension ($43) and hypertension 
($46) were the least expensive (2016 USD). In general, unit 
costs were highest in the US and lowest in Italy. There was 
consistency in costs across European countries, and these 
appeared to differ from those of the US.
ae outcomes and impact of potential cost
The global median outcome expectations for each AE are pre-
sented in Table 5. Cardiac arrest and cardiovascular collapse 
were reported as the most serious AEs and led to the highest 
proportions of procedures delayed or terminated, hospital 
stays, and mortality. When compared to cardiovascular col-
lapse, seizures resulted in a similar proportion of procedures 
delayed (47.6% seizure versus 49.1% cardiovascular collapse) 
and more procedures terminated (71.2% versus 54.1%), but a 
considerably lower mortality rate (0.2% versus 2.4%).
All AEs were associated with the potential for early ter-
mination, delays in subsequent scheduled procedures, and 
inpatient stays. Although incidence of these outcomes could 
not be accurately estimated to allow for overall quantifica-
tion of burden, costs and resource use associated with these 
outcomes were found to be substantial. The cost of canceling 
a procedure, for example, ranged from €183 in Germany 
to €2,780 in France. Early termination of a procedure was 
also found to be expensive in certain settings (eg, $2,320 
in the US).
Per-procedure cost impact
Using available absolute incidence data for the most com-
monly reported AEs (from Germany8,9,19 and the US11,20), 
mean (IQR) increase in cost for a complicated procedural 
sedation was calculated to be €9 (5–13) in Germany and $473 
(339–579) in the US. These data correspond to percentage 
increases over uncomplicated procedures of 12.7% and 
23.3%, respectively.
Discussion
We performed the first comparison of SIVA-defined AEs and 
their associated costs across multiple providers in different 
Table 4 Costs of aes
AE Rank France (EUR) Germany (EUR) Italy (EUR) UK (GBP) US (USD) Worlda (USD)
hypotension 1 23 (18–28) 6 (4–8) 9 (6–13) 14 (10–18) 210 (154–269) 43 (27–68)
Bradycardia 2 11 (7–15) 5 (3–7) 7 (5–10) 14 (9–19) 63 (40–87) 25 (13–45)
Tachycardia 3 43 (31–54) 5 (3–6) 7 (4–11) 68 (43–86) 198 (128–285) 53 (25–101)
Oxygen desaturation (mild, short) 4 16 (11–21) 10 (7–15) 10 (7–14) 20 (11–28) 436 (319–544) 53 (27–98)
hypertension 5 24 (15–30) 6 (5–7) 9 (5–12) 37 (26–49) 114 (70–162) 46 (24–74)
apnea (not prolonged) 6 24 (18–32) 73 (26–113) 18 (11–24) 16 (9–24) 340 (237–434) 70 (36–128)
Oxygen desaturation (mild, long) 7 29 (20–38) 11 (5–15) 11 (7–15) 20 (12–28) 367 (281–459) 57 (31–108)
aW obstruction 8 20 (9–30) 19 (13–28) 15 (7–23) 17 (8–26) 196 (54–291) 57 (7–134)
Failed sedation 9 43 (15–56) 22 (12–31) 15 (12–18) 32 (15–49) 183 (71–310) 80 (30–142)
apnea (long) 10 46 (34–57) 92 (67–119) 16 (9–25) 38 (23–54) 372 (263–493) 110 (59–205)
allergy 11 8 (1–13) 12 (8–16) 16 (8–24) 63 (32–92) 479 (209–707) 48 (11–148)
Oxygen desaturation (severe) 12 55 (41–70) 66 (37–88) 35 (24–45) 39 (22–55) 501 (379–617) 130 (68–223)
Cardiovascular collapse 13 46 (31–62) 122 (83–163) 19 (7–28) 180 (131–233) 1,986 (1,456–2,513) 217 (90–447)
Cardiac arrest 14 70 (40–102) 188 (141–234) 66 (48–84) 597 (441–823) 3,597 (3,108–4,055) 575 (312–921)
seizure 15 24 (10–39) 75 (48–109) 26 (12–41) 78 (26–122) 808 (584–1,015) 116 (29–270)
Notes: Median costs (direct costs, not fully-loaded) were calculated from average treatment patterns by country or globally (from 10,000 bootstrap replicates) multiplied by 
mean costs per ae. Values for ae costs are followed by iQRs in parentheses. aFor global medians (mean values for overall reported procedural sedation costs), costs were 
converted from each corresponding currency to UsD using the average annual currency conversion rate. Ranks range from most frequently (as found to be reported in this 
study) observed aes (1) to least frequently observed aes (15).
Abbreviations: ae, adverse event; aW, airway; iQR, interquartile range.
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Burden of sedation-related adverse events
countries and found consistency of experience with AEs 
in all settings to be universally associated with increased 
costs. Reported rates of AEs in our study were consistent 
with those reported in previous retrospective studies.12–14 
In addition, responses to our surveys from providers with 
experience and responsibility for sedation administration 
suggest that treatment patterns for AEs are largely similar 
across the globe despite differences in medical practice, 
sedatives used, site of service, and geography. In turn, the 
results of our analyses validate growing global concerns for 
the clinical and economic burden of procedural sedation and 
anesthesia in patient care across the world.
Few studies have examined clinical and treatment practice 
regarding sedation, despite the fact that an understanding of 
intervention frequencies may be fundamental to estimating 
the economic burden and costs of sedation-related AEs. One 
recent 21-question survey of endoscopic procedure sedation 
comprised 33 survey responses across 16 European countries 
and concluded that there was a high degree of variability in 
practice and outcomes.21 In contrast, our study featured a 
higher sampling rate per country and found general similarity 
in sedation experiences and practices. In particular, both our 
own and other studies have determined similar trends in the 
use of available patient monitoring modalities, with provid-
ers reporting a relatively high reliance on pulse oximetry 
and blood pressure, with only moderate use of capnography 
among respondents reported.21 The global practice of relying 
on pulse oximetry to monitor for impending AEs may explain 
the consistent rate at which AEs are detected.
To our knowledge, there have been no previous determi-
nations of comprehensive costs for interventions associated 
with sedation-related AEs that can serve as comparison for 
our results. A single study has reported a direct cost for tra-
cheal intubation in the US of $120 in 2009 (approximately 
$134 adjusted to 2016 USD),22 consistent with the global 
mean cost of $133.81 returned in our analysis. Another study 
of medical claims costs associated with sedation-related AEs 
used the US Premier database and yielded vastly different 
results from those of our study.23 However, that analysis 
included legal fees and was disproportionately associated 
with significant morbidity and high downstream costs, while 
ours was focused on direct costs of health care resources.23 
Nevertheless, it is an important reality that increased costs 
resulting from sedation-related AEs are driven by not only 
the costs of interventions used to treat them but also the out-
come or longer-term impact of the complication.
Our study consistently found across countries that even 
relatively minor AEs, such as mild oxygen desaturation, 
added to the cost of care. For the subset of most common AEs 
reported, use of incidence data from other studies resulted 
in calculated cost increases of 13% and 23% above those of 
uncomplicated procedural sedations in Germany and the US, 
respectively. As these estimates use only a subset of all AEs, 
the overall impact of AEs on procedural sedation costs is 
likely higher. This is supported by payer expectation, whereby 
respondents in these countries indicated cost increases of 
78% and 58%, respectively. As calculated increases were 
based only on a subset of AEs for which incidence data 
Table 5 global ae outcomes
AE/outcome Rank Procedures 
delayed (%)
Procedures 
terminated (%)
Unplanned 
inpatient 
stays (%)
Length of 
hospital stay 
(days)
Permanent 
neurological 
defect (%)
Death (%)
hypotension 1 4.0 (1.9–7.2) 4.0 (2.3–8.5) 3.6 (1.9–7.8) 1.3 (1.1–1.7) 0.5 (0.2–0.9) 0.2 (0.1–0.4)
Bradycardia 2 2.4 (1.3–5.1) 2.8 (1.4–5.5) 2.6 (1.4–5.6) 1.2 (1.1–1.9) 0.2 (0.0–0.6) 0.1 (0.0–0.3)
Tachycardia 3 2.1 (1.1–3.5) 2.0 (1.2–2.9) 4.0 (1.1–7.5) 1.4 (1.2–1.8) 0.1 (0.0–0.2) 0.1 (0.0–0.3)
Oxygen desaturation (mild, short) 4 5.3 (2.6–8.9) 4.5 (2.2–8.3) 4.2 (1.8–8.6) 2.2 (1.7–3.3) 0.2 (0.0–0.6) 0.2 (0.0–0.4)
hypertension 5 3.3 (1.5–5.2) 1.9 (1.0–2.8) 2.4 (1.1–3.8) 1.8 (1.4–2.0) 0.0 (0.0–0.1) 0.0 (0.0–0.1)
apnea (not prolonged) 6 6.2 (2.6–9.9) 5.8 (2.2–12.3) 6.5 (1.6–11.4) 1.6 (1.1–2.2) 0.3 (0.1–0.7) 0.1 (0.0–0.1)
Oxygen desaturation (mild, long) 7 6.3 (3.7–9.5) 2.8 (1.1–5.6) 3.6 (2.1–5.9) 1.4 (1.1–1.8) 0.3 (0.1–0.6) 0.2 (0.0–0.3)
aW obstruction 8 5.0 (2.3–10.8) 5.0 (1.5–11.6) 5.0 (2.0–7.0) 1.9 (1.3–2.0) 0.1 (0.0–0.2) 0.0 (0.0–0.2)
Failed sedation 9 6.9 (4.3–10.0) 8.8 (4.4–14.1) 4.5 (1.2–9.9) 1.3 (1.0–1.4) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
apnea (long) 10 6.5 (3.8–12.5) 5.1 (2.2–8.3) 4.7 (2.3–14.3) 1.8 (1.4–2.0) 0.3 (0.1–0.7) 0.1 (0.0–0.2)
allergy 11 9.7 (4.8–20.4) 15.4 (7.2–30.0) 13.8 (6.2–21.7) 2.1 (1.5–3.0) 0.2 (0.0–0.5) 0.3 (0.0–1.3)
Oxygen desaturation (severe) 12 19.1 (9.5–27.4) 15.0 (7.8–20.3) 20.3 (11.0–31.0) 2.2 (1.7–2.6) 0.8 (0.4–1.9) 0.6 (0.3–0.9)
Cardiovascular collapse 13 49.1 (31.7–68.0) 54.1 (35.9–76.5) 56.2 (43.4–79.6) 3.8 (3.0–4.6) 3.0 (2.2–4.0) 2.4 (1.5–3.6)
Cardiac arrest 14 85.5 (50.8–92.4) 94.0 (85.1–97.7) 98.3 (95.5–99.9) 7.6 (5.8–9.0) 24.8 (11.4–39.4) 14.0 (8.1–25.5)
seizure 15 47.6 (25.6–75.6) 71.2 (40.9–96.4) 69.3 (44.7–84.1) 2.4 (2.0–2.9) 1.8 (0.0–8.0) 0.2 (0.0–1.1)
Notes: Median global weighted mean outcomes per ae as percentages or length of unplanned hospital stays in days. Values are derived from 10,000 bootstrap resampling 
replicates of reported survey data. Ranks range from most frequently (as found to be reported in this study) observed aes (1) to least frequently observed aes (15). Values 
in the parentheses are the interquartile range (iQR).
Abbreviations: ae, adverse event; aW, airway.
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were available, the true cost increase may be closer to payer 
expectations. Our estimate also excludes costs from very rare, 
severe AEs and the costs of their potential outcomes. Even 
for the subset of AEs for which incidence data were available, 
the increase in costs can be considerable when considering 
that ~4.7 million procedural (nonoperating room) sedations 
occurred in the US per year over the period from 2010 to 
2014.2 At this level, the subset of AEs would equate to a 
median additional burden of $2.2 billion/year.
Clearly, an important contributor to costs is the frequency 
with which AEs are observed, which is directly related to 
medical practice. Sedation agents used, guidelines followed, 
and choice of monitoring modalities affect both AE frequency 
and treatment response. A common perception among pro-
viders from the authors’ experience is that the occurrence 
of minor events is not seen as an important safety or quality 
indicator. The results presented here, however, demonstrate 
that substantial burden is placed on health care resources 
if these events are not prevented. Furthermore, what begin 
as minor events may herald the oncoming of more serious 
AEs, and medical practice, such as monitoring modality, 
may contribute to the early recognition of these events. 
Economic and provider benefits could therefore potentially 
be realized if greater importance was placed on prevention of 
even minor AEs, and their early recognition should constitute 
good clinical practice.18
An additional contributor to costs and potential expla-
nation of individual- and country-level variation in the 
responses may lie in variations in interpretations of SIVA 
definitions of AEs and interventions. For example, short, mild 
oxygen desaturation is defined by SIVA as arterial oxygen 
saturation between 75% and 90% for 60 seconds, while 
non-prolonged apnea (not connected to AW obstruction) is 
defined as lasting up to 60 seconds. The difference in patient 
impact of 50 seconds of 75% oxygen saturation versus 90% 
oxygen saturation may be associated with vast differences 
in interventions, thereby resulting in vastly different costs. 
Additionally, variability in costs of different interventions 
across countries (eg, AW repositioning and tactile stimula-
tion were found to range from £0 [UK] to $73 [US] and €9 
[France] to $325 [US], respectively) may reflect differences 
in how interventions are locally defined. In general, costs 
were higher in the USA, which may reflect local care prac-
tices, such as more prevalent use of anesthesiology providers 
and use of monitored anesthesia care. The impact of concerns 
for risk management and litigation in the USA after AEs 
occur may also differ from that of other countries and affect 
costs. The current survey was not designed to be able to tease 
apart these potential confounding factors.
Our study design, including our decision to obtain pilot 
data, yielded both advantages and limitations. Our response 
targets were feasible and provided a sample of practice 
and costs across five countries. Our data were collected via 
a third-party intermediate, which allowed us to blind the 
authors to respondents and vice versa. This study presents 
the first estimate of both health care and cost burden specific 
to procedural sedation. As no specific costing methodology 
was enforced by the survey, it is possible that payers provided 
cost data using various methods, limiting comparability. 
On the other hand, we did not include items that could be 
interpreted to have a direct and additional opportunity cost 
(such as early termination of a procedure) in the presented 
direct cost calculations.
In examples where results of our study have coincided 
with published results, value agreements have been good, 
suggesting that our small sample size still yielded results 
consistent with larger, focused studies. Nevertheless, caution 
must be employed in how far our results may be interpreted. 
The pseudorandom sampling of AEs for estimated interven-
tion and outcomes meant that some respondents answered 
questions on treatment practice for AEs that they may not 
have seen within the last year. Nevertheless, we feel it is 
reasonable to assume that given their clinical education 
and previous experience, respondents were able to provide 
sensible reports of their typical treatment patterns. The orga-
nization of the survey also did not allow for all questions to 
be directly linked, such that cause and effect between ques-
tions cannot be guaranteed. Given its undertaking as a pilot 
study, the countries included and the number of responses 
per country were limited with respect to other published 
surveys. With this pilot study completed, the authors are 
keen to extend the reach of this survey in collaboration with 
interested societies.
Conclusion
Clinical experiences with AEs during procedural sedation 
can be generalized internationally, and both minor and severe 
AEs should be recognized to result in poor patient outcomes 
(ie, substantial delays to or cancellation of planned proce-
dures). Furthermore, all sedation-related AEs and by exten-
sion the interventions performed to maintain patient safety 
should be recognized to have associated costs. The findings 
reported here should be considered as a first estimate of event 
burden during procedural sedation. Extension of this survey 
to include more respondents and additional geographies is 
required to clarify the significance of the findings reported.
Our study found that clinical and treatment practices are 
in line with those expected from clinical experience. The cost 
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Burden of sedation-related adverse events
 9. Klare P, Reiter J, Meining A, et al. Capnographic monitoring of mida-
zolam and propofol sedation during ERCP: a randomized controlled 
study (EndoBreath study). Endoscopy. 2016;48(1):42–50.
 10. Lightdale JR, Goldmann DA, Feldman HA, Newburg AR, DiNardo JA, 
Fox VL. Microstream capnography improves patient monitoring during 
moderate sedation: a randomized, controlled trial. Pediatrics. 2006; 
117(6):e1170–e1178.
 11. Qadeer MA, Vargo JJ, Dumot JA, et al. Capnographic monitoring of 
respiratory activity improves safety of sedation for endoscopic cho-
langiopancreatography and ultrasonography. Gastroenterology. 2009; 
136(5):1568–1576; quiz 1819–1820.
 12. Bellolio MF, Gilani WI, Barrionuevo P, et al. Incidence of adverse 
events in adults undergoing procedural sedation in the emergency 
department: a systematic review and meta-analysis. Acad Emerg Med. 
2016;23(2):119–134.
 13. McGrane O, Hopkins G, Nielson A, Kang C. Procedural sedation 
with propofol: a retrospective review of the experiences of an emer-
gency medicine residency program 2005 to 2010. Am J Emerg Med. 
2012;30(5):706–711.
 14. Tohda G, Higashi S, Wakahara S, Morikawa M, Sakumoto H, Kane T. 
Propofol sedation during endoscopic procedures: safe and effec-
tive administration by registered nurses supervised by endoscopists. 
Endoscopy. 2006;38(4):360–367.
 15. Jalili M, Bahreini M, Doosti-Irani A, Masoomi R, Arbab M, 
Mirfazaelian H. Ketamine-propofol combination (ketofol) vs propofol 
for procedural sedation and analgesia: systematic review and meta-
analysis. Am J Emerg Med. 2016;34(3):558–569.
 16. Bellolio MF, Puls HA, Anderson JL, et al. Incidence of adverse events 
in paediatric procedural sedation in the emergency department: a sys-
tematic review and meta-analysis. BMJ Open. 2016;6(6):e011384.
 17. Poh YN, Poh PF, Buang SN, Lee JH. Sedation guidelines, protocols, 
and algorithms in PICUs: a systematic review. Pediatr Crit Care Med. 
2014;15(9):885–892.
 18. Mason KP, Green SM, Piacevoli Q; International Sedation Task Force. 
Adverse event reporting tool to standardize the reporting and tracking 
of adverse events during procedural sedation: a consensus document 
from the World SIVA International Sedation Task Force. Br J Anaesth. 
2012;108(1):13–20.
 19. Friedrich-Rust M, Welte M, Welte C, et al. Capnographic monitoring of 
propofol-based sedation during colonoscopy. Endoscopy. 2014;46(3): 
236–244.
 20. Mehta PP, Kochhar G, Albeldawi M, et al. Capnographic monitoring 
in routine EGD and colonoscopy with moderate sedation: a prospec-
tive, randomized, controlled trial. Am J Gastroenterol. 2016;111(3): 
395–404.
 21. Vaessen HH, Knape JT. Considerable variability of procedural sedation 
and analgesia practices for gastrointestinal endoscopic procedures in 
Europe. Clin Endosc. 2016;49(1):47–55.
 22. Gupta D, Wang H. Cost-effectiveness analysis of flexible optical 
scopes for tracheal intubation: a descriptive comparative study of reus-
able and single-use scopes. J Clin Anesth. 2011;23(8):632–635.
 23. Saunders R, Erslon M, Vargo J. Modeling the costs and benefits of 
capnography monitoring during procedural sedation for gastrointestinal 
endoscopy. Endosc Int Open. 2016;4(3):E340–E351.
of AEs, however, was found to be more than anticipated in 
certain cases, which may drive further discussion about the 
best ways to optimize patient safety to provide value-based 
health care. The findings of our analyses also suggest that 
even minor AEs can add considerable costs when considering 
the increasing number of procedural sedations performed. 
Costs of sedation-related AEs may be partially controlled 
by improvements in monitoring to reduce their occurrence 
and the need for interventions to treat them.
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